Abbott launches new generation of Afinion test system
Abbott announced the launch of its Afinion 2 analyzer in the United States. This marks the newest generation of the Afinion system, which builds on the company’s heritage in empowering patients with information about their health.
The Afinion 2 streamlines and simplifies the delivery of accurate measurements of hemoglobin A1C, or HbA1C, and albumin to creatinine ratio results at the point of care. The system also arms health care professionals with information to make quick and accurate medical decisions, which allows for more time to be dedicated to counseling patients in a single office visit, the company said.
“By delivering rapid HbA1C and ACR test results, the Afinion 2 analyzer does more than streamline care; its life-changing technology helps people living with diabetes get the most out of their healthcare visits,” Elizabeth Balthrop, divisional vice president of Cardiometabolic and Informatics at Abbott, said. “Within a single visit, patients can obtain real-time feedback and insights on their condition, have an informed discussion with their provider and leave with a defined care plan.”
Afinion 2’s platform also offers all-in-one connectivity to laboratory and hospital information systems, and a quieter experience for clinicians and patients. Health care professionals can also use the device in such out-patient settings as clinics, community health centers, hospitals and long-term care facilities.
“Bringing point-of-care HbA1C into my practice was a game changer in terms of helping my patients with diabetes live better and spend less time at my office,” Saleh Aldasouqi, chief of the division of endocrinology at Michigan State University, said. “With the Afinion analyzer, I have reliable HbA1C results in just three minutes, which allows me to actively manage their care at the time of the patient encounter.”
No comments found
Drug stores to play bigger diabetes role
CVS Health senior educator Kristene Diggins and others involved in the fight against diabetes said they expect drug stores and retail clinics to play a bigger role in coming years.
(To view the full Category Review, click here.)
“Our retail partners are committed to early intervention and making community pharmacies the focal point for care,” Trividia Health president and chief executive Scott Verner said last month after his company acquired Freedom Meditech and announced its plans to begin offering that company’s noninvasive six-second eye scan, a test that can screen for diabetes and other chronic conditions by detecting the presence of advanced glycation products, or AGEs, in the lens of the eye.
“As the number of in-store clinics continues to grow and the number of screenings continues to expand, this technology will fill the void,” he said.
Also lending hope to the quest to help more patients get their diabetes under control is the recent development of monitors that do not require diabetes patients to draw blood for testing.
The first such device — a wristwatch that used an electric current to pull small amounts of fluid through the skin without having to prick it — was approved by the Food and Drug Administration more than a decade ago, but was taken off the market soon after its launch because more than half of the patients who used the watch experienced skin irritation and sores.
Noninvasive glucose monitoring returned to the market late last year when the FDA gave its approval to Dexcom’s G5 Mobile Continuous Glucose Monitoring System, the first agency-approved continuous glucose monitoring system that can be used to make diabetes treatment decisions without confirmation via a traditional fingerstick test. Previously, the system was approved to complement, not replace, fingerstick testing.
“This may allow some patients to manage their disease more comfortably and may encourage them to have routine dialogue with their healthcare providers about the use of real-time continuous glucose monitoring in diabetes management,” Dr. Alberto Gutierrez, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, said when the agency approved the system.
To read about four of the hottest diabetes products out now, check out the slideshow above.
Want more OTC news? To read February’s Cough-Cold Report, click here.
No comments found